Life Science News

  • Purchase from an NHL sports and entertainment venue marks an important milestone in The Gummy Project's multi-channel sales strategy.
  • The Gummy Project's Peachy Bees and Watermelon Sharks will be featured for sale in all concessions, starting with the Winnipeg Jets pre-season home opener.
  • Peachy Bees and Watermelon Sharks now available in an NHL sports and entertainment venue, major grocery chains, a national airline, hotels (in both US and Canada) and one of the largest passenger ferry lines in the world.

The Gummy Project (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce it has received a purchase order from The Canada Life Centre, home of the National Hockey League's Winnipeg Jets and American Hockey League's Manitoba Moose.

"We are absolutely thrilled that our Peachy Bees and Watermelon Sharks will be available for fans to enjoy at Jets and Moose games," said Charlie Lamb, President & CEO of GUMY. "Our multi-channel sales strategy now includes high traffic sports and entertainment venues, with Canada Life Centre marking our entrance into this sector and a key milestone for the Company. In a very short time period, we have been able to form partnerships with and have our gummies for sale in major grocery chains, a national airline, hotels (both in the US and Canada), one of the largest passenger ferry systems in the world and now a professional sports stadium and we very much look forward to continuing to execute our strategic expansion both in Canada and the US."

Canada Life Centre (formerly MTS Centre and Bell MTS Place) is an indoor arena in downtown Winnipeg, Manitoba. The arena is the home to the National Hockey League's Winnipeg Jets and their American Hockey League affiliate, the Manitoba Moose. The arena stands on the former Eaton's site and is owned and operated by True North Sports & Entertainment. The 440,000 square building was constructed opened on November 16, 2004, replacing the since-demolished Winnipeg Arena. It has a capacity of 15,321 for hockey and 16,345 for concerts.

"Being born in Winnipeg myself, it's a dream come true to know that our gummies will be sold at Winnipeg Jets games," said Anthony Gindin, CMO of GUMY. "This also marks our expansion into the exciting new sales vertical of sports and entertainment venues."

About The Gummy Project

We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free 1(888) 556-9656
E-mail: investors@shopgummies.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/138511

News Provided by Newsfile via QuoteMedia

GUMY:CC
The Gummy Project Enters State of Texas with Purchase Order from 5-star Luxury Hotel Located in Austin, Texas

The Gummy Project Enters State of Texas with Purchase Order from 5-star Luxury Hotel Located in Austin, Texas

  • Purchase Order from 5-star luxury hotel in Austin, Texas marks the achievement of another milestone in The Gummy Project's ongoing highly strategic multi-channel sales strategy
  • The Peachy Bees and Watermelon Sharks are expected to be for sale in each of the hotel's guest room private bars

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce that it has received a purchase order for its Peachy Bees and Watermelon Sharks from a 5-star luxury hotel located in Austin, Texas (the "Luxury Hotel").

"Entering an additional US state and having our gummies for sale at this Luxury Hotel is another significant achievement for the Company as we continue to expand in both Canada and the US," said Charlie Lamb, President and CEO of GUMY.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Officially Launches in U.S. Market with Ecommerce Site and Nationwide Shipping

The Gummy Project Officially Launches in U.S. Market with Ecommerce Site and Nationwide Shipping

  • U.S. customers can now purchase Watermelon Sharks and Peachy Bees at www.shopgummies.com.
  • Product is shipped nationwide across the U.S. within 5-7 days.

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce the official launch of its U.S. ecommerce site at www.shopgummies.com.

"We are excited to officially launch our products into the U.S. market, which is a major milestone for the company," said Charlie Lamb, CEO at GUMY. "We are now ready to ship product to all 50 states, which represents a tremendous growth opportunity for the Company beyond the existing Canadian market."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Warrant Repricing

The Gummy Project Announces Warrant Repricing

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") announces today that it has reduced the exercise price of 7,261,700 warrants (the "Amended Warrants") of the Company. All dollar figures are quoted in Canadian dollars.

The reduced exercise price is $0.05. The Amended Warrants include an accelerated expiry provision such that the exercise period of each of the Amended Warrants is reduced to 30 days if for any 10 consecutive trading days, the closing price of the Company's common shares is equal or greater than $0.05, with the 30-day expiry period commencing on the day the Company disseminates a press release announcing the commencement of the accelerated expiry period.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Grant of Stock Options

The Gummy Project Announces Grant of Stock Options

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYD) ("GUMY" or the "Company") announces that it has issued a total of 2,300,000 stock options pursuant to its incentive stock option plan ("Plan") to consultants which vest on the grant date. Each option entitles the holder to subscribe for one common share of the Company for $0.06 for a period of 5 years, subject to the terms of the Plan. Over the past quarter, 1,664,800 options have lapsed or been cancelled.

About The Gummy Project

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
CSE Bulletin: Consolidation - The Gummy Project Inc.

CSE Bulletin: Consolidation - The Gummy Project Inc.

 The Gummy Project Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 12,250,156 common shares.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan

Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. –

Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company's management team will provide a corporate update on Sunday, December 11, 2022, at 10:00 AM EST 9:00 CST, in conjunction with poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, LA. The webcast event will include a comprehensive review of current clinical data for Aptose's lead compound tuspetinib, formerly HM43239, a myeloid kinase inhibitor, as well as an update on luxeptinib, Aptose's oral, dual lymphoid and myeloid kinase inhibitor.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer

Late-Breaking TROPiCS-02 Analysis Shows that Trodelvy Demonstrates Consistent Efficacy Across Trop-2 Expression Levels –

Trop-2 is Highly Expressed in 90% of Breast Cancers

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

  • Collaboration leverages HotSpot's Smart Allostery™ drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseases
  • HotSpot to receive an upfront cash payment of $40 million with potential for further milestones and royalties

ABBVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.

"This collaboration with HotSpot has the potential to deliver an entirely new target class of modulators to patients with serious autoimmune diseases, such as systemic lupus erythematosus, and will help to further strengthen our robust immunology pipeline," said Jonathon Sedgwick , Ph.D., vice president and global head of discovery research, AbbVie.  "HotSpot's drug discovery platform has been able to identify molecules that bind to IRF5 in a predictable, reproducible manner potentially enabling effective drugging of what has been considered an undruggable target."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes International (CaMEO-I) study on neck pain with headache in people with and without migraineResults from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine in Europe will also be presented

NORTH CHICAGO, Ill. , Dec. 6, 2022 /PRNewswire/ -- ABBVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16 th European Headache Federation Congress 2022 (EHC 2022) taking place in Vienna, Austria , December 7-10 . A total of 15 abstracts will cover a wide range of studies across AbbVie's migraine portfolio, including data on onabotulinumtoxinA and atogepant.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022

AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR

Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×